# A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®

> **NCT06614907** · PHASE1 · COMPLETED · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 198 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** QL2108 injection
- **DRUG:** Dupixent®

## Key facts

- **NCT ID:** NCT06614907
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-31
- **Primary completion:** 2024-11-15
- **Final completion:** 2024-12-27
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06614907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06614907, "A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06614907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*